Measles

• 1. Introduction

  ›

  Measles has been killing people since at least the 4th century BC, and the Persian physician Muhammad ibn Zakariya al-Razi described it as "more to be dreaded than smallpox" more than a thousand years ago. Its name likely traces to Middle Dutch or Middle High German, where masel meant "blemish" or "blood blister" - a word that captures the signature red rash visible on almost every person who contracts it. Today, measles affects roughly 10 million people a year, primarily in Africa and Asia, and it remains one of the leading causes of death from a vaccine-preventable disease.

  What makes measles so threatening is a combination of extreme contagiousness, a quiet incubation that enables silent spread, and a hidden aftermath that can cripple a child's immune system for years. Nine out of ten people who lack immunity and share living space with an infected person will become infected. The rash and fever that mark the illness are only part of the story. How did a disease that was declared eliminated from the Americas in 2016 surge back to claim nearly 870,000 cases globally in 2019? Why can a vaccine that is 97-99% effective after two doses still fail to stop outbreaks? And what did researchers mean when they discovered that measles doesn't just make you sick - it makes you forget how to be immune?

• 2. The Disease Itself

  ›

  Fever is the first sign. It begins around 10-14 days after exposure, climbs in a stepwise fashion, and can peak between 103 and 105 degrees Fahrenheit. At that stage, the illness looks like many respiratory infections: cough, runny nose, inflamed eyes. Clinicians call this trio "the three C's" - cough, coryza, and conjunctivitis.

  Two to four days into the fever, a clinician who looks inside the cheeks might spot Koplik spots - tiny white lesions, sometimes described as grains of salt, clustered on reddened areas opposite the molars. They are pathognomonic for measles, meaning their presence alone confirms the diagnosis. The catch is that they appear for only a short time and disappear before most people seek medical care.

  Three to five days after symptoms begin, the characteristic rash arrives. It starts on the back of the ears or the face, then spreads downward across the body. The rash is the immune system doing its work - the cellular and humoral immune response clearing infected skin cells. Once the rash appears, the disease is actually near its turning point. Uncomplicated cases typically resolve within 7-10 days of rash onset.

  The virus is contagious from four days before the rash appears to four days after, meaning a person can spread measles before any visible sign marks them as ill. The rash itself eventually stains, shifting from red to dark brown before fading. People who were vaccinated but have incomplete immunity may develop a modified form of the disease, with a longer incubation and milder symptoms - but they are still contagious, just less so.

• 3. Complications and Immune Amnesia

  ›

  Approximately 30% of measles cases involve at least one complication, and even children who were previously healthy can face serious illness requiring hospitalization. Pneumonia, encephalitis, and blindness rank as the most severe direct effects of the virus. Pneumonia alone accounts for 56-86% of measles-related deaths.

  Measles encephalitis can occur at several different points during illness. Acute post-infectious encephalitis typically emerges in the first week of infection, bringing very high fever, severe headache, convulsions, and altered mental state. A more unusual and devastating form, subacute sclerosing panencephalitis, can develop years after the original infection. This progressive and ultimately fatal condition affects about 1 in 600 unvaccinated infants under 15 months who contract measles.

  Corneal damage can lead to blindness, and the risk rises sharply in people with vitamin A deficiency. In underdeveloped nations with high rates of malnutrition and poor healthcare, fatality rates from measles have been as high as 28%. In immunocompromised people, the fatality rate is approximately 30%.

  Perhaps the least visible complication is immune amnesia. The measles virus kills the memory cells that hold the body's accumulated record of past infections - the antibodies built up against other bacteria and viruses over a lifetime. After recovering from measles, a child's immune system generates new memory lymphocytes, but these are specific to measles alone. Prior immunity to other diseases is erased. Population studies suggest this suppression typically continues for 2-3 years after measles infection, raising childhood mortality from other infectious diseases during that window. The measles vaccine uses an attenuated strain that does not deplete immune memory, which means vaccination protects against this hidden consequence as well.

• 4. The Virus and How It Spreads

  ›

  Measles virus is a single-stranded, enveloped RNA virus belonging to the genus Morbillivirus within the family Paramyxoviridae. Its closest known relative is rinderpest, the cattle virus that was eradicated in 2001. There are 24 strains of the measles virus, divided into eight clades designated A through H.

  The virus enters the body through the respiratory tract, where it binds to a receptor called SLAM on the surface of immune cells, specifically macrophages and dendritic cells. Those cells carry the virus deeper into the immune system, passing it to B cells, T cells, thymocytes, and hematopoietic stem cells, which disseminate it to other organs during the incubation period. About five to seven days into infection, the virus reaches epithelial cells and spreads via intercellular pores and nectin-4 receptors. The resulting cough aerosolizes the virus and sends it onward to the next host.

  Measles remains infectious in suspended respiratory droplets for up to two hours. It is not easily spread through objects because ultraviolet light and heat inactivate it within a few hours. The virus cannot establish a reservoir in other animals, though mountain gorillas are believed to be susceptible. Humans are its only natural host, which is also why targeted vaccination campaigns can theoretically eliminate it. The reproductive number - a measure of how many people each infected person infects - has been estimated as broadly as 3.7 to 203.3, depending on the population studied. That range reflects how dramatically the virus's spread depends on the density and immunity of the community around it.

• 5. The Vaccine and Herd Immunity

  ›

  In 1954, John Enders and Thomas C. Peebles isolated the measles virus from David Edmonston, a 13-year-old boy in the United States. Enders brought experience from poliovirus work and used similar tissue culture techniques - first growing the Edmonston strain in human kidney tissue, then in amniotic membrane tissue culture, and finally in chick embryo culture. Over three years, this process weakened the virus to the point where it could generate immunity without causing disease. While at Merck, Maurice Hilleman further attenuated the Edmonston B strain, and the resulting vaccine became widely available in the United States in 1963.

  Early versions of the vaccine produced fever and rash in some recipients. Further attenuation produced the Schwartz strain in 1965 and the Edmonston-Enders strain in 1968; Edmonston B was discontinued in 1975. A killed version of the measles vaccine was used between 1963 and 1967 but was dropped because it offered inferior protection and created the risk of atypical measles in recipients. The live-attenuated vaccine was eventually combined with vaccines against mumps and rubella to create the MMR vaccine, licensed for use in the United States in 1971. Adding the varicella vaccine produced the MMRV vaccine, licensed in 2005.

  One dose of the MMR vaccine given at twelve months of age or older is 95% effective. A second dose raises protection to 97-99%. Life-threatening reactions occur in fewer than one per million vaccinations. Because measles is so contagious, more than 95% of any community must be vaccinated to achieve herd immunity. Vaccination drove an 80% decrease in measles deaths between 2000 and 2017 and cut the global death toll from 2.6 million in 1980 to 73,000 by 2014. The epidemiologist M.S. Bartlett identified in 1957 that a community smaller than roughly 250,000 people cannot sustain measles circulation, because the virus exhausts its supply of susceptible hosts.

• 6. Resurgence and Outbreaks

  ›

  The United States was declared free of circulating measles in 2000, with fewer than 1,000 cases in the following decade. That changed in 2019, when 1,282 individual cases were confirmed across 31 states - the greatest number since 1992. Many of the 2019 cases clustered in communities with lower vaccination rates, including the Orthodox Jewish neighborhoods of Brooklyn and Rockland County, New York, and Clark County, Washington, where nearly one in four kindergartners lacked vaccinations. Washington governor Jay Inslee declared a public health emergency, and the New York City mayor declared a public health emergency in April 2019.

  The 2014-2015 Disneyland outbreak in California spread to 147 people across seven U.S. states, Mexico, and Canada. Of those 159 cases reported to the CDC between January and April 2015-70% were traced to a single late December 2014 exposure, and 48% of those infected were unvaccinated. The initial source of the virus was never identified.

  In 2025, an outbreak centered in West Texas resulted in the first measles death in the United States since 2015: an unvaccinated school-aged child. By March 2025, the CDC had recorded 483 confirmed cases across 20 states, 2 deaths, and 70 hospitalizations - exceeding the entire 2024 total of 285 cases.

  Globally, cases reported in the first three months of 2019 were 300% higher than the same period in 2018. In 2022, an estimated 136,000 deaths occurred, mostly among unvaccinated or under-vaccinated children under five. In November 2024, the WHO and CDC reported a 20% increase in cases in 2023, with nearly half of major outbreaks and 64% of individual cases occurring in Africa. Europe saw 127,350 cases in 2024, the highest caseload in the region since 1997, with Romania reporting 30,692 of those cases.

• 7. History and Deep Roots

  ›

  Measles evolved from rinderpest, a cattle disease, and a precursor of the virus began infecting humans as early as the 4th century BC. Sometime between 1100 and 1200 AD, the measles virus fully diverged from rinderpest and became a distinct pathogen adapted exclusively to humans. This timing fits the observation that measles requires a susceptible population of over 500,000 to sustain itself - a threshold that was reached in European cities during the medieval period.

  The first systematic written description of measles as a disease distinct from smallpox and chickenpox came from the Persian physician Muhammad ibn Zakariya al-Razi (860-932), who published The Book of Smallpox and Measles. At the time of Razi's writing, outbreaks were believed to be limited, suggesting the virus had not yet fully adapted to spread widely.

  When measles reached populations with no prior exposure, the results were catastrophic. In 1529, an outbreak in Cuba killed two-thirds of the indigenous people who had survived smallpox. Two years later, measles was responsible for the deaths of half the population of Honduras. Measles killed 20% of Hawaii's population in the 1850s and more than 40,000 Fijians - approximately one-third of the population - in 1875.

  The 1846 measles outbreak in the Faroe Islands offered a rare opportunity for systematic study. Measles had not been seen on the islands for 60 years, so almost no residents had acquired immunity. Three-quarters of the residents fell ill, and more than 100 died. The physician Peter Ludvig Panum observed the outbreak and established that measles spread through direct contact between contagious people and those who had never been infected. He also documented the immunity conferred by illness and calculated the incubation period, providing a foundation that researchers would build on for the next century - until John Enders isolated the virus in 1954 and the first vaccine followed nine years later.